Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Department of Pathology and Clinical Laboratory, National Cancer Center Hospital, Tokyo, Japan.
Thorac Cancer. 2020 Dec;11(12):3618-3621. doi: 10.1111/1759-7714.13713. Epub 2020 Oct 21.
Pembrolizumab is the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed death-ligand 1 (PD-L1) expression tumor proportion score (TPS) ≥50%. The benefit of pembrolizumab in patients with advanced NSCLC and poor performance status (PS ≥3) is limited, even when the tumor is PD-L1-expression-positive. We retrospectively reviewed a total of four NSCLC cases with high PD-L1 expression (TPS ≥50%) and poor PS. The only patient with very high PD-L1 expression (TPS 100%) responded to pembrolizumab, but none of the three patients with high PD-L1 expression (50%-80%) responded to pembrolizumab. In conclusion, pembrolizumab can serve as a treatment option for patients with poor PS, if PD-L1 expression TPS is 100%.
帕博利珠单抗是 PD-L1 表达肿瘤比例评分（TPS）≥50%的晚期非小细胞肺癌（NSCLC）的标准一线治疗药物。对于 PS≥3 的晚期 NSCLC 患者，即使肿瘤 PD-L1 表达阳性，帕博利珠单抗的获益也有限。我们回顾性分析了 4 例 PD-L1 高表达（TPS≥50%）且 PS 差的 NSCLC 患者。唯一 PD-L1 表达非常高（TPS 100%）的患者对帕博利珠单抗有反应，但 PD-L1 表达高（50%-80%）的 3 例患者均未对帕博利珠单抗有反应。总之，如果 PD-L1 表达 TPS 为 100%，则帕博利珠单抗可作为 PS 差患者的治疗选择。
